吉西他滨联合DF化疗方案治疗晚期食管癌的临床研究  

Clinical Study of Gemcitabine Combined with DF Chemotherapy Regimen in the Treatment of Advanced Esophageal Cancer

作　　者：侯万聪 尹路 张君 Hou Wancong;Yin Lu;Zhang Jun(The Third Department of Oncology,Nanyang First People’s Hospital,Nanyang,Henan,473000,China)

机构地区：[1]南阳市第一人民医院肿瘤内三科,河南南阳473000

出　　处：《黑龙江医学》2024年第18期2248-2250,共3页Heilongjiang Medical Journal

摘　　要：目的:研究吉西他滨联合DF化疗(顺铂+5-氟尿嘧啶)方案治疗晚期食管癌对血清肿瘤标志物、血管新生及预后的影响。方法:选取2021年1月—2022年12月南阳市第一人民医院收治的82例晚期食管癌患者作为研究对象,采用随机数表法将其分为对照组(DF化疗)和观察组(DF化疗+吉西他滨),每组各41例。观察两组患者治疗后的血清肿瘤标志物水平[糖类抗原125(CA125)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)]、血管新生情况[转化生长因子β1(TGF-β1)、血管内皮生长因子(VEGF)、基质金属蛋白酶9(MMP-9)]。结果:观察组疾病总缓解率(ORR)、疾病总控制率(DCR)均高于对照组,差异有统计学意义(χ^(2)=4.201、4.479,P<0.05);治疗后,观察组CA125、CA9-9、CEA水平均低于对照组,差异有统计学意义(t=10.553、8.804、5.903,P<0.05);治疗后,观察组TGF-β1、VEGF、MMP-9水平均低于对照组,差异有统计学意义(t=8.817、10.741、15.080,P<0.05);两组患者骨髓抑制、肝肾功能异常等Ⅰ~Ⅳ级毒副反应发生率比较,差异无统计学意义(χ^(2)=0.265、0、0.091、0.345、0.064,P>0.05);半年内,观察组复发率低于对照组,差异有统计学意义(χ^(2)=4.205,P<0.05)。结论:吉西他滨联合DF化疗方案治疗晚期食管癌可以提高疗效,降低血清肿瘤标志物水平,减少血管新生,毒副反应可耐受,预后较好。Objective:To study the effect of gemcitabine combined with DF chemotherapy(cisplatin+5-fluorouracil)on advanced esophageal cancer on serum tumor markers,angiogenesis and prognosis.Methods:82 patients with advanced esophageal cancer hospitalized from January 2021 and December 2022 were selected and divided into the control group(DF chemotherapy)and observation group(DF chemotherapy+gemcitabine)to observe the serum levels of tumor markers[sugar antigen 125(CA 125),sugar antigen 19-9(CA19-9),carcinoembryonic antigen(CEA)],angiogenesis[transforming growth factorβ1(TGF-β1),vascular endothelial growth factor(VEGF),matrix metalloproteinaseenzyme 9(MMP-9)].Results:The total disease response rate(ORR)and total disease control rate(DCR)were higher than the control group(χ^(2)=4.201,4.479;P<0.05).CA125,CA9-9 and CEA levels were lower than the control group(t=10.553,8.804,5.903;P<0.05).TGF-β1,VEGF and MMP-9 were lower than the control group(t=8.817,10.741,15.080;P<0.05).Incidence of classⅠtoⅣtoxic and side effects,such as bone marrow suppression and renal function abnormalities(χ^(2)=0.265,0,0.091,0.345,0.064;P>0.05).The recurrence rate in the observation group was lower than the control group(χ^(2)=4.205,P<0.05).Conclusion:The combination of gemcitabine and DF chemotherapy can improve efficacy in advanced esophageal cancer,reduce serum tumor marker level,reduce angiogenesis and tolerate toxic side effects,and have better prognosis.

关 键 词：吉西他滨 顺铂+5-氟尿嘧啶化疗方案 食管癌 

分 类 号：R735.1[医药卫生—肿瘤]